Intravenously Administered M6229 in Critically Ill Sepsis Patients

NCT05208112 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Sepsis
Septic Shock
Critical Illness

Interventions

DRUG: M6229

Sponsor

A.P.J. Vlaar

Collaborators

[object Object]
[object Object]
[object Object]